The ATP cassette-binding (ABC) gene superfamily contains more than 40 members, many of which are involved in cellular lipid transport. The most prominent example is ABCA1, mutations in which affect plasma high-density lipoprotein (HDL) cholesterol concentration. ABCC6 is another member of the ABC gene family, and mutations in ABCC6 were recently shown to cause pseudoxanthoma elasticum (PXE). A Canadian patient with PXE was referred for assessment of moderately severe type IV hyperlipoproteinemia with hypoalphalipoproteinemia, which was refractory to pharmacological treatment. We identified intron-exon boundaries of ABCC6 to sequence genomic DNA from this patient to find the disease mutation. We report (1) identification of a set of amplification primers for the 31 exons of ABCC6; (2) identification of the ABCC6 RϾX1164 nonsense mutation in the PXE subject with dyslipidemia; (3) identification of common amino acid variants and silent nucleotide variants in ABCC6, with a range of allele frequencies across ethnic groups; (4) evidence consistent with a possible pseudogene encoding 9 exons with sequence homology to ABCC6; and (5) association of the ABCC6 RϾQ1268 variant with plasma triglyceride and HDL cholesterol. The results suggest that ABCC6 may be a determinant of plasma lipoproteins.
Introduction
Mutations in the gene encoding ATP-binding cassette transporter 1 (ABCA1) cause Tangier disease (TD) and familial deficiency of high-density lipoprotein (HDL) cholesterol (Bodzioch et al. 1999; Brooks-Wilson et al. 1999; Rust et al. 1999; Remaley et al. 1999; Brousseau et al. 2000; Wang et al. 2000) . There is also some evidence that a common variation in ABCA1 may be a determinant of plasma lipoprotein concentration (Wang et al. 2000; Clee et al. 2001) . ABCA1 is part of a multigene family comprising more than 40 ABC transporters, many of which transport a variety of lipids, including cholesterol, phospholipids, bile acids, and very long chain fatty acids (Klucken et al. 2000) . Two other members of the ABC transporter family, namely ABCG5 and ABCG8, were recently shown to play a crucial role in sterol absorption through their implication as causative genes for sitosterolemia (Berge et al. 2000; Lee et al. 2001) . In addition, expression of several members of the ABC multigene family is regulated by lipoproteins (Klucken et al. 2000) . These attributes of the ABC multigene family -their implication as determinants of lipoproteins, general involvement in the absorption and transport of lipids, and regulation in vitro by HDLsuggests that other family members could be involved in plasma lipoprotein variation. In this regard, the presence of HDL cholesterol abnormalities in patients with mutations in other members of the ABC multigene family might justify the study of other family members as determinants of plasma lipoprotein traits.
Pseudoxanthoma elasticum (PXE; autosomal recessive OMIM 264800 and autosomal dominant OMIM 177850) is an inherited systemic disorder affecting the connective tissue, and is characterized by progressive calcification of the elastic fibers of the eye, skin, and vasculature (Neldner 1988) . Patients typically have decreased visual acuity, characteristic skin lesions, and peripheral vascular disease (Neldner 1988) . Recently, missense, nonsense, and splice site mutations in the ABCC6 gene (OMIM 603234) were found to cause autosomal recessive, autosomal dominant, and sporadic forms of PXE (Le Saux et al. 2000; Bergen et al. 2000; Ringpfeil et al. 2000 Ringpfeil et al. , 2001 . ABCC6 (OMIM 603234), also called MRP6, encodes a 1503-amino acid plasma membrane protein with a molecular weight of 165 kD and 17 membrane-spanning helices grouped into three transmembrane domains (Le Saux et al. 2000; Bergen et al. 2000; Ringpfeil et al. 2000) . Although the ABCC6 product likely transports xenobiotics, the physiological targets are not known.
Cross-sectional studies involving relatively large numbers of PXE patients indicate a higher-than-expected prevalence of hypertriglyceridemia (Neldner 1988 ) and depressed plasma HDL cholesterol (Renie et al. 1984) compared with age-and sex-matched control subjects. Our interest in ABCC6 as a candidate gene for plasma lipoproteins was kindled by the observation of long-standing refractory dyslipidemia -elevated triglycerides and low HDL cholesterol -in a patient with autosomal recessive PXE. To find the ABCC6 mutation in this PXE subject, we defined a set of genomic DNA amplification primers for most of the ABCC6 coding sequence. We found that our PXE subject with dyslipidemia was homozygous for a premature truncation mutation in ABCC6. We also found several common variants in ABCC6, allowing for assessment of association of variation at this locus with plasma lipoproteins.
Subjects and methods

Subjects
PXE subject. The index patient, an orphan, was diagnosed with PXE as a child on the basis of characteristic skin findings affecting his neck, chest, and flexor regions of both extremities, in addition to the typical bilateral angioid retinal changes, which were more pronounced in the right eye. He was diagnosed with dyslipidemia at 30 years of age. Untreated plasma concentrations of total cholesterol, triglyceride, low-density lipoprotein (LDL) and HDL cholesterol (mean Ϯ SD from three determinations) were 5.07 Ϯ 1.23 mmol/L, 4.88 Ϯ 3.76 mmol/L, 2.56 Ϯ 1.17 mmol/L, and 0.56 Ϯ 0.33 mmol/L, respectively, consistent with moderate type IV hyperlipidemia with hypoalphalipoproteinemia. He received dietary and lifestyle advice, and drug treatment, which included fibric acid derivatives, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, and combinations of these drugs at various times. The most normal triglyceride and HDL cholesterol concentrations while on treatment were 1.88 mmol/L and 0.76 mmol/ L, respectively, despite excellent compliance. Plasma triglycerides and HDL cholesterol had not been within the reference range for age and sex since treatment began.
FHA subjects. We selected from our dyslipidemia archives eight subjects who each conformed to biochemical criteria for heterozygous familial hypoalphalipoproteinemia (FHA), namely, plasma HDL cholesterol and/or apolipoprotein (apo) AI concentration below the fifth percentile for age and sex, with plasma triglyceride concentration below the fiftieth percentile for age and sex. None of these subjects had any physical manifestations compatible with PXE or TD. These subjects had all been shown to have normal sequences for the APOA1, LCAT, and ABCA1 genes encoding apo AI, lecithin:cholesterol acyl transferase, and ABC-1, respectively.
Control samples. Samples from normolipidemic subjects taken from six ethnic groups (38 Europeans, 44 Oji-Cree, 30 Inuit, 36 Africans, 37 Chinese, and 38 South Asians) were studied to determine allele and genotype frequencies.
Inuit sample for lipoprotein association. For this analysis, we studied normolipidemic Canadian Inuit (Hegele et al. 1997) . Briefly, 516 randomly selected individuals 18-80 years of age participated; of these, 281 reported themselves as being Inuit, 112 as being of mixed ethnic background, 92 as being of European background (white), and 31 as being of an ethnic background other than Inuit, mixed, or white. Blood samples were obtained with informed consent. The first exclusion criterion was a self-reported non-Inuit ancestry. The second exclusion criterion was an inadequate blood sample for genetic determinations, which left 216 subjects for the association analysis.
Determining the intron-exon boundaries of ABCC6
Genomic DNA was isolated from the whole blood of all study subjects using an established method (Puregene, Gentra Systems, Minneapolis, MN, USA). We used our established method to determine intron-exon boundaries of ABCC6 (Wang et al. 2000) . Human ABCC6 sequence information was obtained from human chromosome 16 genomic bacterial artificial chromosome (BAC) clone CIT987SK-A-962B4 (GenBank accession number U91318) and human ABCC6 cDNA sequence (GenBank accession number NM_001171). Once the intron-exon boundaries were determined, the ABCC6 gene-coding region could be sequenced using polymerase chain reaction primers designed to amplify the genomic region containing each individual exon, the intron-exon boundaries, and Ͼ50bp of intronic sequence. In addition, the primers were chosen to share an optimum annealing temperature of 59°C (Table I) , which allowed for optimal use of a single amplification apparatus.
ABCC6 genomic mutations and polymorphisms
Samples from nine subjects were analyzed extensively: the PXE subject and the eight subjects with FHA described earlier. Direct genomic DNA sequencing of the individual exons was carried out using the primers in Table I . All amplification reactions were carried out in a 50-µl mixture containing 32 pmol of each primer, 0.2 mM each of deoxyadenosine triphosphate, deoxycytidine, triphosphate, deoxyquanosine triphosphate, and deoxythymidine triphosphate, 1.5 mM MgCl 2 , 50 mM KCl, 20 mM Tris HCl (pH 8.4), and 2.5 U Taq Platinum DNA polymerase (GIBCO BRL, Life Technologies, Mississauga, ON, Canada). Each amplifi-cation cycle consisted of a denaturation step at 94°C, an annealing step at 59°C, and an extension step at 72°C for 30s each, followed by a final extension step for 10min at 72°C and cooling to 4°C. The amplification products were then run on 1.5% agarose gels and purified using QIAEX II gel extraction kit (QIAGEN Santa Clara, CA, USA). Purified amplification products were directly sequenced using the ABI 377 Prism Automated DNA Sequencer. DNA sequences were aligned using ABI Sequence Navigator software.
Once a sequence variant was identified in a sample, its presence was confirmed by fresh reamplification and resequencing of the culprit exon from the patient sample on another day. If the DNA change, which was usually a singlenucleotide polymorphism (SNP), affected a restriction endonuclease recognition site, restriction fragment length polymorphism analysis would be used as the basis of a rapid method to genotype the specific SNP for the purposes of determining allele and genotype frequencies in various ethnic groups, and for studies of association with plasma HDL cholesterol. In contrast, if the DNA change or SNP did not affect a restriction endonuclease recognition site, genotypes would be inferred from electropherogram traces from direct genomic DNA sequencing to determine allele and genotype frequencies in Caucasians only.
Statistical analysis
The significance of deviations of the observed genotype frequencies from those predicted by the Hardy-Weinberg equations were evaluated with chi-square tests. SAS (Version 6.12) was used for statistical comparisons involving plasma lipoproteins (SAS/STAT guide). Associations with plasma lipoproteins were assessed using an amino acid polymorphism that had sufficient heterozygosity or information content, thus ensuring sufficient numbers of subjects with each genotype for parametric statistical analysis. To test whether common variation in ABCC6 was associated with variation in plasma HDL cholesterol, we thus genotyped the ABCC6 RϾQ1268 polymorphism in a previously reported normolipidemic Inuit sample (Ringpfeil et al. 2000) . We assumed a dominant model for Q1268, in which the genotype variable was set at 0 for subjects with R1268/ R1268 genotype and 1 for subjects with the Q1268/R1268 and Q1268/Q1268 genotype. Covariates in the ANOVA were age, sex, body mass index (BMI), and the presence of current cigarette smoking (Ringpfeil et al. 2000) . The proportion of variation in a plasma lipoprotein concentration from each covariate was estimated from partial regression coefficients.
Results
Intron-exon boundaries of ABCC6 and primers for genomic sequencing Intron-exon boundaries were identified for 31 exons (Table 1) . The sequencing strategy outlined earlier resulted in the identification of homozygosity for a novel ABCC6 mutation in the PXE subject with dyslipidemia, namely, R1164X (OMIM 603234.0013). This mutation was absent from 446 control alleles from 223 subjects of all ethnic groups. No other mutations were found (Le Saux et al. 2000; Bergen et al. 2000; Ringpfeil et al. 2000 Ringpfeil et al. , 2001 .
Common amino acid variants in ABCC6
DNA from eight subjects with FHA was sequenced, resulting in the identification of two common amino acid variants in ABCC6, namely, VϾA614 in exon 14 and RϾQ1268 in exon 27 (Table 2 ). Restriction analysis with endonucleases TaqI and MspI for VϾA614 and RϾQ1268, respectively, was used to determine the genotype and allele frequencies in the normolipidemic ethnic samples. The ABCC6 VϾA614 and RϾQ1268 polymorphisms were each polymorphic in all ethnic groups (Table 2) .
Common silent variants in ABCC6
The sequencing strategy outlined earlier resulted in the identification of many common silent variants in ABCC6 (Table 2) . Although none of these altered a naturally occurring restriction endonuclease recognition site, genotypes were easily determined from electropherogram tracings of genomic DNA sequences of the individual exons. This allowed for calculation of the genotype and allele frequencies in Caucasians only. None of the genotype frequencies for any polymorphism shown in Table 2 deviated from the expectations of the Hardy-Weinberg equation in any study sample.
Atypical sequence variants: a pseudogene for ABCC6?
We observed disparities in the ABCC6 genomic DNA sequence from the screening sample and sequences that had been previously published. Allele frequencies of these polymorphisms were each 0.5 from a total of 34 alleles from normolipidemic subjects, and all subjects were heterozygotes. Seven of these monomorphic heterozygous polymorphisms changed the amino acid sequence: namely, AϾT78, EϾK125, AϾV158, RϾG265, KϾE281, IϾV319, and AϾT360, and one of them, QϾX378, encoded a premature termination. Taken together, the results suggest the presence of a related gene, or pseudogene, for ABCC6, which shares homology with the first nine exons, and also has notable amino acid differences compared with the reference ABCC6 gene sequence, culminating with premature termination at codon 378.
Association of ABCC6 RϾQ1268 with plasma lipoprotein variation Table 3 shows baseline features of the Inuit sample studied for association of ABCC6 RϾQ1268 genotype with plasma lipoprotein traits. Men and women differed significantly for all variables except total and LDL cholesterol. Table 4 shows genotype distribution and allele frequencies for ABCC6 RϾQ1268 in the Inuit sample overall and according to gender. There was no significant deviation of any genotype frequency from the Hardy-Weinberg expectation.
Analysis of variance revealed that the ABCC6 RϾQ1268 genotype was a determinant of HDL cholesterol and triglyceride concentration (Table 5) . Age was a determinant of total cholesterol, HDL, LDL, and apo B; sex was a determinant of HDL cholesterol and apo AI; and BMI Least squares mean (ϮSE) plasma HDL cholesterol (adjusted for age and sex) was 1.37 Ϯ 0.39 mmol/L for the 154 subjects with the ABCC6 R1268/R1268 genotype and 1.49 Ϯ 0.32 mmol/L for the 62 subjects with either the ABCC6 Q1268/R1268 or the Q1268/Q1268 genotypes (Bonferroni P Ͻ 0.05). Least squares mean (Ϯ SE) plasma triglycerides (adjusted for age and sex) were 1.16 Ϯ 0.63 mmol/L for the 154 subjects with the ABCC6 R1268/ R1268 genotype and 0.94 Ϯ 0.37 mmol/L for the 62 subjects with either the ABCC6 Q1268/R1268 or the Q1268/Q1268 genotypes (Bonferroni P Ͻ 0.05). Thus, the ABCC6 Q1268 allele was associated with lower plasma triglycerides and higher plasma HDL cholesterol. Multivariate regression analysis indicated that the ABCC6 RϾQ1268 genotype accounted for 11.1% of variation in plasma HDL cholesterol (P ϭ 0.024) and for 11.0% of variation in plasma triglyceride (P ϭ 0.05). Post hoc analyses revealed no associations with plasma apo AI (data not shown).
Discussion
We report (1) identification of a set of amplification primers for all 31 of the ABCC6 exons that amplify at a single annealing temperature, allowing for optimal use of hardware; (2) identification of a rare ABCC6 mutation in a subject with PXE, type IV hyperlipidemia and hypoalphalipoproteinemia; (3) identification of several common amino acid variants and silent nucleotide variants in ABCC6, with a range of allele frequencies across ethnic groups; (4) evidence consistent with a pseudogene encoding 9 exons that share sequence homology with ABCC6; and (5) association of the common ABCC6 RϾQ1268 variant with plasma triglyceride and HDL cholesterol in Inuit. The ABCC6 Q1268 allele was associated with lower plasma triglycerides and higher plasma HDL cholesterol, suggesting that ABCC6 may determine plasma lipoproteins.
The results indicate that sequencing directly from genomic DNA and analysis of attributes of detected SNPs such as allele frequency, genotype frequency, and deviations from Hardy-Weinberg equilibrium can help define regions that have attributes of pseudogenes or gene duplication. Such results would not necessarily arise from experiments that analyzed cDNA only, indicating the power to obtain additional molecular information afforded by sequencing directly from genomic DNA.
It is not clear whether the plasma lipoprotein abnormalities in our single PXE patient were attributable to his rare ABCC6 mutation. Lipoprotein profiles were not reported from other subjects with this mutation (Neldner 1988; Renie et al. 1984) . In general, plasma lipid profiles have not been very carefully characterized in most patients with PXE. Cross-sectional studies involving a total of Ͼ100 PXE subjects have suggested a prevalence of both hypertriglyceridemia (Neldner 1988; Renie et al. 1984) and depressed HDL cholesterol (Neldner 1988 ) that is approximately twice as high as in the general population. Taken together with the association of the ABCC6 RϾQ1268 polymorphism with variation in plasma triglycerides and HDL cholesterol, ABCC6 may be a determinant of variation in plasma lipoproteins.
ABCC6 belongs to the ABC gene subfamily C, which includes ABCC1-5, CFTR, ABCC8, and ABCC9 (encoding the sulfonylurea receptor) (Borst et al. 2000) . The exact biological function of ABCC6 is unknown, although it may transport hydrophobic xenobiotics (Borst et al. 2000) . In addition, the mechanism underlying development of PXE from mutations in the ABCC6 transmembrane receptor gene product is unknown. A role for the ABCC6 gene product in lipid transport and metabolism is possible for several reasons. For instance, ABCC6 shares considerable homology of both predicted structure and domain organization compared with other members of the ABC gene family, of which at least 10 have been implicated to be involved in cellular lipid transport (Borst et al. 2000) . However, in contrast to other members of the ABC gene family, expression of the ABCC6 gene product appears not to be regulated in vitro by plasma lipoproteins.
The common ABCC6 RϾQ1268 variant occurs within the 3Ј-intracytoplasmic domain of ABCC6 (Le Saux et al. 2000; Bergen et al. 2000; Ringpfeil et al. 2000 Ringpfeil et al. , 2001 . Although originally proposed to be a disease mutation, subsequent work indicated that ABCC6 RϾQ1268 was a common polymorphism (Germain et al. 2000) , which is consistent with our findings. Our present analysis provides evidence that common variation in ABCC6 is associated with variation in quantitative plasma lipoprotein traits. There is no explanation at present for how this common variant might affect plasma lipoprotein metabolism. Indeed, the observed association might be related to linkage disequilibrium with a functional variant at or near the ABCC6 locus, such as the closely linked ABCC1 and PM5 genes and/or other unknown genes on 16p13.1 (Lee et al. 2001) . However, the ABCC6 locus is distinct from the reported chromosome 16q locus linked to familial combined hyperlipoproteinemia (Aouizerat et al. 1999) .
In summary, we defined primers to amplify the ABCC6 coding region. We used these primers in direct genomic DNA sequencing to identify a nonsense mutation in a subject with PXE and dyslipidemia. We found several SNPs within the coding sequence of ABCC6, of which one was associated with variation in plasma lipoproteins in a normolipidemic sample. The results suggest that ABCC6 mutations, both rare and common, are associated with variation in plasma lipoproteins.
